Factors in Learning And Plasticity: Macular Degeneration
A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mec
| Condition(s) | Central Visual Impairment, Macular Degeneration |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function, and preservation of sight. The comparison of different training and outcome factors is in line with the NIMH RDOC framework and studies in an aging population are consistent with the mission of the NIA. |
| Who can participate | Inclusion Criteria: * Aged 18-89 * Severely impaired vision in both eyes (20/100 or worse) * diagnosis of Macular Degeneration by an Ophthalmologist * Light sensitivity in the macular retina that is at least 10 dB units worse than in peripheral regions, as demonstrated by a scanning laser ophthalmoscope (MAIA) * Medical record review indicating this level of disease severity has been present for at least 2 years * Reside within 50 miles of study site Exclusion Criteria: * Pacemaker or any ferromagnetic metal implanted in their body * Metal of any type implanted in their head (limited dental work is acceptable) * Claustrophobia * Being hearing-impaired * Weight over 300 pounds * Maximum body girth over 60 inches * Previous serious head injury * Presence of hallucinations or delusions * Exce |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Lead sponsor | University of Alabama at Birmingham |
| Locations | Birmingham, Alabama, United States |
| Start date | 2022-11-01 |
| NCT ID | NCT05454124 |
| Official listing | https://clinicaltrials.gov/study/NCT05454124 |